Geneva Advisors LLC Maintains Position in Cardiovascular Systems, Inc. (CSII)
Geneva Advisors LLC continued to hold its stake in Cardiovascular Systems, Inc. (NASDAQ:CSII) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,330 shares of the medical device company’s stock at the end of the second quarter. Geneva Advisors LLC’s holdings in Cardiovascular Systems were worth $494,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of the company. Teachers Advisors LLC boosted its stake in Cardiovascular Systems by 62.1% in the fourth quarter. Teachers Advisors LLC now owns 95,895 shares of the medical device company’s stock valued at $2,322,000 after buying an additional 36,735 shares in the last quarter. Nationwide Fund Advisors boosted its stake in Cardiovascular Systems by 26.1% in the first quarter. Nationwide Fund Advisors now owns 42,815 shares of the medical device company’s stock valued at $1,211,000 after buying an additional 8,854 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Cardiovascular Systems during the first quarter valued at about $1,657,000. First Quadrant L P CA purchased a new stake in Cardiovascular Systems during the first quarter valued at about $1,730,000. Finally, State of New Jersey Common Pension Fund D purchased a new stake in Cardiovascular Systems during the first quarter valued at about $424,000. Institutional investors and hedge funds own 75.34% of the company’s stock.
Cardiovascular Systems, Inc. (CSII) opened at 29.15 on Thursday. The stock has a 50 day moving average of $31.11 and a 200-day moving average of $29.89. The company’s market cap is $961.69 million. Cardiovascular Systems, Inc. has a one year low of $21.29 and a one year high of $33.11.
Cardiovascular Systems (NASDAQ:CSII) last announced its quarterly earnings data on Wednesday, August 2nd. The medical device company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.07. The company had revenue of $52.90 million for the quarter, compared to analyst estimates of $51.98 million. Cardiovascular Systems had a positive return on equity of 0.88% and a negative net margin of 0.87%. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.15) EPS. On average, equities analysts predict that Cardiovascular Systems, Inc. will post $0.01 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/31/geneva-advisors-llc-maintains-position-in-cardiovascular-systems-inc-csii.html.
Several analysts have issued reports on CSII shares. TheStreet upgraded shares of Cardiovascular Systems from a “d” rating to a “c-” rating in a research note on Thursday, May 4th. BidaskClub upgraded shares of Cardiovascular Systems from a “hold” rating to a “buy” rating in a research note on Friday, June 9th. Bank of America Corporation lowered shares of Cardiovascular Systems from a “neutral” rating to an “underperform” rating in a report on Wednesday, June 21st. Needham & Company LLC reissued a “buy” rating and issued a $37.00 price target (up previously from $32.00) on shares of Cardiovascular Systems in a report on Friday, July 14th. Finally, Zacks Investment Research lowered shares of Cardiovascular Systems from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Three investment analysts have rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Cardiovascular Systems presently has a consensus rating of “Hold” and a consensus price target of $33.83.
In other Cardiovascular Systems news, insider Laura Gillund sold 2,350 shares of the firm’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $30.42, for a total value of $71,487.00. Following the transaction, the insider now owns 88,633 shares in the company, valued at approximately $2,696,215.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Scott R. Ward sold 5,529 shares of the firm’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $30.41, for a total value of $168,136.89. Following the completion of the transaction, the chief executive officer now owns 282,536 shares in the company, valued at approximately $8,591,919.76. The disclosure for this sale can be found here. Insiders sold a total of 18,034 shares of company stock worth $551,759 in the last 90 days. 3.60% of the stock is currently owned by insiders.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Stock Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related stocks with our FREE daily email newsletter.